Full Press Release Details
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference.
SGMT
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
Key Takeaway: Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
Price reaction · baseline $5.5 (2023-10-17 close) · hit after-hours · 1 other SGMT headline(s) in the window, move may be shared
day 0 close
+0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease